Top 10 Best Bioconjugation Services of 2026

Bachem’s engagement model targets programs that need repeatable chemistry-to-manufacturing transfer, not only bench-scale synthesis. Contract deliverables typically include conjugation execution, purification through preparative chromatography, and method support for stability and release-style characterization. The strongest fit is teams that already have a target payload, linker concept, and acceptance criteria and need a partner to translate them into a controlled process with measurable outputs.

A tradeoff shows up when an internal team needs full transparency of every in-process parameter because Bachem’s outputs emphasize scientific deliverables and batch results rather than line-by-line operational controls. Bachem fits best for antibody–drug conjugate programs where conjugation yield, aggregation behavior, and free payload quantitation must stay consistent across development stages.

Samsung Biologics fits teams that treat bioconjugation as part of a larger CMC delivery plan. Conjugation development is typically paired with purification and analytical characterization steps designed to quantify free payload, residual antibody, and aggregate risk using orthogonal methods. The service shape favors structured workflows that map chemistry choices to measurable CQAs such as drug-to-antibody ratio and stability under defined handling conditions.

A tradeoff appears when projects need highly iterative chemistry exploration with frequent route changes because manufacturing-style governance can slow down late pivots in linker or conjugation strategy. Samsung Biologics works best when a primary conjugation approach is selected early and the team needs scale-up and method consistency for tech transfer and later batch characterization.

GenScript supports antibody–drug conjugates, antibody–oligonucleotide conjugates, and peptide and protein labeling work through defined chemistry and downstream purification steps. The execution model pairs conjugation with characterization such as chromatography-based separation and LC-MS readouts that inform conjugation yield, free payload quantitation, and residual unconjugated material. Engagement fit is strongest when a sponsor wants a structured laboratory program from conjugation through release-style analytics, not just a single synthetic step.

A key tradeoff is that projects requiring highly bespoke internal analytics or unusual release specification formats may need extra coordination to align assay endpoints and reporting. It fits best for programs that can provide target chemistry inputs and acceptance criteria early, then iterate based on analytical outputs rather than requesting frequent midstream re-scoping of linker strategy or conjugation route. It is also well suited when a sponsor wants continuity across conjugation execution and orthogonal analytical checks for aggregation and size distribution.

Catalent is a bioconjugation services provider that delivers chemistries and downstream processing for ADCs and related conjugates at outsourced manufacturing scale. The differentiator is its ability to run end-to-end workflows that combine conjugation execution, purification and aggregate control, and analytically guided release testing. Its model supports tech transfer and scale-up work across batches, which matters for teams moving from small feasibility runs to production-like conditions.

Abzena performs bioconjugation service work that turns biologics into conjugates for antibody–drug conjugates and related formats. The core delivery covers conjugation execution with controlled analytical characterization, including quantitation of unconjugated species and aggregate behavior.

Abzena also supports purification workflows to reduce carryover and stabilize downstream bioanalytical results. The service is organized around documented process steps that map chemistry execution to analytical release-style testing.

Lonza is a bioconjugation service provider built for late-stage execution of conjugation and analytics across multiple therapeutic modalities. The vendor supports workflows that span conjugation chemistry, intermediate and final purification, and release-relevant characterization using chromatography and mass spectrometry.

Lonza’s delivery model is geared toward project governance with defined handoffs between synthesis, analytics, and method-linked specifications. It is especially well suited for programs that need process control around yield, purity, and stability as conjugates move from development to tech transfer.

Thermo Fisher Scientific brings bioconjugation depth through integrated discovery, conjugation execution, and analytical characterization across multiple therapeutic modalities. The service lineup supports both antibody–drug conjugates and antibody–oligonucleotide conjugates, with chemistry routes that cover common coupling families and linker strategies.

Process packages typically include purification steps and orthogonal release analytics such as chromatography and MS-based characterization to quantify conjugation outcomes and residuals. For teams needing scale-out studies, throughput planning and tech transfer support are positioned around repeatable workflows rather than one-off synthesis.

Creative Biolabs provides bioconjugation chemistry services that cover multiple antibody and biomolecule labeling workflows, including ADC-style drug-linker conjugation and oligonucleotide or protein labeling use cases. The service focus is practical delivery across conjugation execution, purification, and analytical release packages needed for downstream development work.

Creative Biolabs also supports workflow branching based on linker type and conjugation strategy, which helps teams compare random versus site-directed outcomes. Lab execution is paired with characterizations such as size and species distribution analysis so teams can track aggregate formation and residual unconjugated starting material.

CellMosaic delivers bioconjugation services focused on converting biomolecules into conjugates using controlled chemistries and downstream purification. The service workflow centers on defining conjugation targets such as ADC or oligonucleotide formats, selecting a linker and coupling approach, and generating batches with analytical readouts.

CellMosaic also supports method development inputs around yield tracking, free payload quantitation, and aggregation or residual species characterization. The operational differentiator is how the provider links chemistry decisions to release-ready analytical outputs for nonclinical and clinical manufacturing handoffs.

BOC Sciences supports bioconjugation work spanning antibody–drug conjugates, antibody–oligonucleotide conjugates, and protein labeling services. The company delivers conjugation chemistry execution with purification and analytical confirmation workflows that include chromatographic separation and LC-MS style characterization.

BOC Sciences is also oriented toward method design around linker behavior and stability needs, which matters when release specifications and aggregate analysis are part of the success criteria. Delivery tends to fit teams that need managed execution of bioconjugation experiments rather than building a full in-house chemistry stack.